Side effects associated with<unk>  include vaginal discharge, hot flashes, and diaphoresis. More serious adverse effects are similar to those of estrogens and estrogen receptor modulators. These include, but are not limited to, thromboembolism, allergic reactions, fatigue, and headache, and others could occur. There are other additional adverse effects.<unk>  is a selective estrogen receptor modulator. As such, many of the effects produced by estrogens are produced by<unk> . The boxed warning of the medication indicates<unk>  may thicken the endometrium, which could lead to unusual bleeding and endometrial cancer. For women taking estrogens, concurrently taking a type of drug called a progestin has been shown to decrease the occurrence of endometrial hyperplasia. In theory, progestins may be expected to attenuate<unk> 's effects on endometrial thickening. However clinical trials confirming this have not been conducted. Like estrogens,<unk>  also may increase the risk for cardiovascular events, including "stroke, coronary heart disease, venous thromboembolism," and others. The risk of thrombotic and hemorrhagic strokes is given as 0.72 and 1.45 per 1,000 women, while that of deep vein thrombosis is estimated to be 1.45 per 1,000 women. The risks of these adverse events in women taking<unk>  are lower than those in women taking estrogen alone in the form of oral conjugated estrogens. Studies have not documented the relative risk compared with women taking estrogen/progestin therapy.
Ospemifene
Veristrat
Sesquimustard
Acolbifene
Toremifene
Tiotixene
Patiromer
Mitapivat